Seres Therapeutics, Inc. (MCRB)
Largest Insider Buys in Sector
MCRB Stock Price History Chart
MCRB Stock Performance
About Seres Therapeutics, Inc.
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal …
Insider Activity of Seres Therapeutics, Inc.
Over the last 12 months, insiders at Seres Therapeutics, Inc. have bought $0 and sold $98,345 worth of Seres Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Seres Therapeutics, Inc. have bought $9.18M and sold $675,966 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 2,912,748 shares for transaction amount of $9.18M was made by AFEYAN NOUBAR () on 2022‑07‑05.
List of Insider Buy and Sell Transactions, Seres Therapeutics, Inc.
| 2024-11-18 | Sale | CEO and President | 2,505 0.0014% | $0.54 | $1,355 | +27.79% | ||
| 2024-11-18 | Sale | Chief Legal Officer and EVP | 878 0.0005% | $0.54 | $475 | +27.83% | ||
| 2024-11-18 | Sale | See Remarks | 735 0.0004% | $0.54 | $398 | +27.76% | ||
| 2024-11-18 | Sale | See Remarks | 927 0.0005% | $0.54 | $501 | +27.83% | ||
| 2024-11-18 | Sale | See Remarks | 977 0.0005% | $0.54 | $528 | +27.83% | ||
| 2024-10-28 | Sale | CEO and President | 8,748 0.0045% | $0.69 | $6,037 | 0.00% | ||
| 2024-10-28 | Sale | Chief Legal Officer and EVP | 4,259 0.0022% | $0.69 | $2,939 | 0.00% | ||
| 2024-10-28 | Sale | See Remarks | 2,983 0.0015% | $0.69 | $2,059 | 0.00% | ||
| 2024-10-28 | Sale | See Remarks | 3,984 0.0021% | $0.69 | $2,749 | 0.00% | ||
| 2024-10-28 | Sale | See Remarks | 4,334 0.0022% | $0.69 | $2,991 | 0.00% | ||
| 2024-08-16 | Sale | CEO and President | 2,518 0.0015% | $0.84 | $2,115 | 0.00% | ||
| 2024-08-16 | Sale | Chief Legal Officer and EVP | 873 0.0005% | $0.84 | $733 | 0.00% | ||
| 2024-08-16 | Sale | See Remarks | 728 0.0004% | $0.84 | $612 | 0.00% | ||
| 2024-08-16 | Sale | See Remarks | 1,128 0.0007% | $0.84 | $948 | 0.00% | ||
| 2024-08-16 | Sale | See Remarks | 923 0.0006% | $0.84 | $775 | 0.00% | ||
| 2024-08-16 | Sale | See Remarks | 973 0.0006% | $0.84 | $817 | 0.00% | ||
| 2024-08-05 | Sale | See Remarks | 24,480 0.0137% | $1.08 | $26,534 | -34.15% | ||
| 2024-05-15 | Sale | CEO and President | 2,435 0.0016% | $0.94 | $2,289 | -9.07% | ||
| 2024-05-15 | Sale | Chief Legal Officer and EVP | 843 0.0005% | $0.94 | $792 | -9.07% | ||
| 2024-05-15 | Sale | See Remarks | 1,090 0.0007% | $0.94 | $1,025 | -9.07% |
Insider Historical Profitability
| AFEYAN NOUBAR | 5875711 3.4414% | $0.77 | 2 | 1 | +40% |
Institutional Investor Ownership
| Flagship Pioneering | $17.89M | 15.26 | 23.12M | 0% | +$0 | 1.17 | |
| Fidelity Investments | $17.53M | 14.96 | 22.65M | +16.83% | +$2.53M | <0.01 | |
| BlackRock | $5.28M | 4.51 | 6.83M | -7% | -$397,929.95 | <0.0001 | |
| The Vanguard Group | $5.21M | 4.45 | 6.73M | +12.15% | +$564,716.79 | <0.0001 | |
| Hudson Bay Capital Management LP | $4.2M | 3.58 | 5.42M | +25.57% | +$855,070.96 | 0.03 |